EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Fri, 22.12.2023
PAION AG: Sale of the business operations
Aachen (Germany), 22 December 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, PA8) announces that PAION AG and its German subsidiary, PAION Deutschland GmbH, with the approval of the preliminary insolvency administrator of PAION AG and PAION Deutschland GmbH, ...
PAION AG: Sale of the business operations
Aachen (Germany), 22 December 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, PA8) announces that PAION AG and its German subsidiary, PAION Deutschland GmbH, with the approval of the preliminary insolvency administrator of PAION AG and PAION Deutschland GmbH, a...
PAION AG cancelled guidance for financial year 2023
Aachen (Germany), 24 November 2023 - The specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, PA8) announces that against the background of the applications filed for the opening of insolvency proceedings, the forecast for the current financial year 2023 previously...
PAION AG CHANGES FROM PRIME STANDARD TO GENERAL STANDARD
Aachen, 22. November 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange: PA8) announces that the stock exchange listing of PAION AG will be changed from the Prime Standard to the General Standard of the regulated market of the Frankfurt Stock Exchan...
PAION AG SIGNS STRATEGIC COOPERATION AGREEMENT WITH YICHANG HUMANWELL
Aachen, Germany, 21 November 2023 - The Specialty Pharma Company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange: PA8) announces the signing of a Memorandum of Understanding ("MOU") on a strategic cooperation with Yichang Humanwell at the China Innovation Conference. T...
PAION AG HAS FILED FOR THE OPENING OF INSOLVENCY PROCEEDINGS - PRELIMINARY INSOLVENCY ADMINISTRATOR APPOINTED
Aachen (Germany), 31 October 2023 - The specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) announces that, in accordance with the ad hoc announcement dated October 26, 2023, it filed fo...
PAION AG: Filing an application for the opening of insolvency proceedings
Aachen (Germany), 26 October 2023 - The specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) announces that it will immediately file for insolvency proceedings. The background to the filing is the fact that irregularities ...
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
CORPORATE NEWS
PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights
Aachen, 20 October 2...
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Ad-hoc Announcement
Inside information according to Article 17 EU Market Abuse Regulation (MAR)
PAION AG to issue approximately 4.8 million shares at EUR 1.9...
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
CORPORATE NEWS
PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million
Two investors have committed to backstop th...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .